14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AURA vs JBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas JBIO carries 38.0/100 (SELL) at $15.34 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although JBIO compares more favorably head-to-head, both AURA (31.1/100 SELL) and JBIO (38.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile JBIO is in a Breakdown options structure phase (RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs JBIO. Trailing 12-month operating profitability (AURA 0.0% vs JBIO 0.0%) and valuation multiples (AURA N/M vs JBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AURA vs JBIO Key Questions & Quantitative Answers
As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas JBIO carries 38.0/100 (SELL) at $15.34 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although JBIO compares more favorably head-to-head, both AURA (31.1/100 SELL) and JBIO (38.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile JBIO is in a Breakdown options structure phase (RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
JBIO leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with JBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus N/A for JBIO. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JBIO.
AURA and JBIO trade at balanced relative valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas JBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus JBIO (-89.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, JBIO carries 73.0% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.